How can I use CMC development consultants to support early formulation design and stability studies for a new drug candidate?

CMC development consultants can be very useful in the early, pre-IND phase to help you make faster, better decisions about formulation selection, process feasibility, and stability strategy for a new drug candidate. Here’s a practical way to use them.

1) Start with a clear CMC development brief

Give the consultant enough context to design a sensible plan. Include:

• Molecule type: small molecule, biologic, peptide, oligo, etc.
• Target product profile: route of administration, dose, patient population, intended release profile
• Known liabilities: solubility, hygroscopicity, polymorphism, oxidation, hydrolysis, aggregation, etc.
• Material available: API amount, purity, salt form, polymorph, particle size, excipient restrictions
• Timeline and stage: discovery, lead optimization, candidate selection, preformulation, IND-enabling
• Regulatory target: FDA, EMA, ICH expectations, pediatric, sterile, inhalation, etc.

This lets them focus on what matters instead of doing generic work.

2) Use them for preformulation risk assessment

A good consultant will help you identify the main developability risks early, such as:

• Solubility and dissolution limits
• pH-dependent stability
• Solid-state form changes
• Oxidation, photolysis, or moisture sensitivity
• Compatibility with likely excipients
• Adsorption, aggregation, or precipitation risk
• Container/closure interactions

Typical outputs:

• A risk assessment
• A preformulation study plan
• Recommended analytical methods
• A shortlist of formulation approaches to test

3) Have them design a formulation screening strategy

For early formulation design, consultants can build a structured screening matrix rather than trying formulations ad hoc.

They may evaluate:

• Salt and polymorph selection
• pH and buffer screening
• Solubilizers: surfactants, cosolvents, cyclodextrins
• Solid dosage options: amorphous dispersions, micronization, nanoparticles
• Liquid dosage options: solution, suspension, lipid-based systems
• Biologic formulations: buffers, stabilizers, tonicity agents, surfactants, preservatives if needed

A good consultant will help you choose the smallest set of experiments that answers the most important questions.

4) Use them to build a stability study plan that matches development stage

Early stability studies should be designed to learn quickly, not just to generate shelf-life data.

Consultants can help you define:

• Stress studies: heat, humidity, light, oxidation, freeze-thaw, agitation
• Accelerated and long-term conditions
• Solution vs. solid-state stability
• Forced degradation for method development and impurity understanding
• In-use stability if relevant
• Packaging and closure compatibility
• Sampling timepoints and storage conditions

They should also help align the plan with ICH guidance where appropriate, while recognizing that early-stage work is often exploratory.

5) Ask them to set up or review analytical methods

Early formulation and stability work depends heavily on good analytics. Consultants can help:

• Select key assays for potency, purity, impurities, degradants
• Develop or troubleshoot HPLC/UPLC, LC-MS, dissolution, particle size, pH, osmolality, viscosity, moisture content, Karl Fischer, SEC, etc.
• Define stability-indicating methods
• Set acceptance criteria for early development studies

If the methods are weak, the formulation conclusions will be weak too.

6) Use them for decision-making, not just testing

The best value from consultants is often in interpreting data and making decisions:

• Which formulation is most likely to succeed?
• What is the main instability mechanism?
• Which excipient or packaging change is worth testing next?
• Is the candidate good enough to advance, or should you modify the molecule/salt/form?

Ask them to provide go/no-go criteria and a recommendation at each stage.

7) Define deliverables up front

Good deliverables might include:

• Preformulation development plan
• Formulation screening matrix
• Stability protocol
• Analytical method development plan or gap assessment
• Data summary and interpretation
• Recommended lead formulation
• Risk register and next-step plan

This keeps the engagement focused and measurable.

8) Use the consultant as an extension of your internal team

They can be especially valuable if you don’t have in-house expertise in:

• Solid-state chemistry
• Biophysical characterization
• Sterile formulation
• Lyophilization
• Early clinical CMC strategy
• Regulatory CMC expectations

A strong consultant should be able to work with your chemists, biologists, analytical team, and CROs/CDMOs.

9) Common mistakes to avoid

• Starting too late, after key API decisions are already locked in
• Providing too little material or too little molecule knowledge
• Running too many unstructured experiments
• Focusing only on accelerated stability without understanding degradation mechanisms
• Choosing a consultant without relevant modality experience
• Not aligning formulation work with the intended clinical route and target profile

10) How to choose the right consultant

Look for someone who has:

• Experience with your modality and dosage form
• Hands-on formulation and stability expertise
• Familiarity with regulatory expectations
• Strong analytical judgment
• Ability to translate data into practical decisions
• Experience working with startups or lean development teams

If you want, I can also help you with:

1. a sample scope of work for a CMC consultant,
2. a preformulation/stability study plan template, or
3. a list of interview questions to vet a consultant.